Document Detail

Determinants of final infarct size and incidence of aborted infarction in patients treated with primary coronary intervention and adjunctive abciximab therapy.
MedLine Citation:
PMID:  18278214     Owner:  NLM     Status:  MEDLINE    
AIMS: Assess the determinants of final infarct size in patients successfully treated with primary percutaneous coronary intervention (PCI) and abciximab therapy and check whether infarct abortion may occur.
PATIENTS, METHODS: In 208 patients we examined the parameters that predict final infarct size and the incidence of aborted infarction, defined by completely normal perfusion and regional wall motion plus >50% left ventricular ejection fraction (LVEF) in gated single-photon emission computed tomography (SPECT) acquired at one month.
RESULTS: In linear regression analysis, sex (p<0.0001), high cholesterol (p<0.05), Killip class (p<0.0001), symptom-to-reperfusion time (p<0.001), admission ST segment elevation (p<0.0001), infarct related artery (p<0.05), and pre-procedural TIMI flow (p<0.002) were significant univariate predictors of final infarct size. In multiple linear regression analysis, symptom-to-reperfusion time (p<0.001), Killip class (p<0.0001), ST segment elevation (p<0.003), and sex (p<0.03) remained significant predictors, model R(2)=0.53. Aborted infarction was registered in 32 patients, more frequently female (59% versus 21%, p<0.00001), older (p<0.02), with larger prevalence of TIMI grade 3 (p<0.05) and lower ST segment elevation at admission (p<0.05).
CONCLUSIONS: Sex, reperfusion delay, and initial infarct severity as indicated by Killip class and/or ST segment elevation appear the determinants of final infarct size in patients treated with primary PCI. The presence of aborted infarction seems related to the same factors and to preserved TIMI 3 flow.
R Sciagrà; G Parodi; B Sotgia; D Antoniucci; A Pupi
Related Documents :
8358474 - St segment monitoring for coronary artery reocclusion following thrombolytic therapy an...
2644054 - Heart rate adjustment of st segment depression for improved detection of coronary arter...
2721254 - Acute anterior wall myocardial infarction presenting with positive t waves and without ...
16846444 - A segmental polynomial model of ventricular electrograms as a simple and efficient morp...
22237734 - Surgery for atrial fibrillation: recent progress and future perspective.
12002264 - Cardioprotective effects of chronic hypoxia and ischaemic preconditioning are not addit...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Nuklearmedizin. Nuclear medicine     Volume:  47     ISSN:  0029-5566     ISO Abbreviation:  Nuklearmedizin     Publication Date:  2008  
Date Detail:
Created Date:  2008-02-18     Completed Date:  2008-05-06     Revised Date:  2013-05-24    
Medline Journal Info:
Nlm Unique ID:  7609387     Medline TA:  Nuklearmedizin     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  56-61     Citation Subset:  IM    
Nuclear Medicine Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Anticoagulants / therapeutic use
Combined Modality Therapy
Immunoglobulin Fab Fragments / therapeutic use*
Middle Aged
Myocardial Infarction / drug therapy*,  pathology,  radionuclide imaging*,  surgery
Platelet Aggregation Inhibitors / therapeutic use
Radiopharmaceuticals / diagnostic use
Retrospective Studies
Technetium Tc 99m Sestamibi / diagnostic use
Tomography, Emission-Computed, Single-Photon
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Anticoagulants; 0/Immunoglobulin Fab Fragments; 0/Platelet Aggregation Inhibitors; 0/Radiopharmaceuticals; 109581-73-9/Technetium Tc 99m Sestamibi; X85G7936GV/abciximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Computer-aided diagnosis in two-phase 201Tl-SPECT of thoracic lesions.
Next Document:  Aspects of 6-[18F]fluoro-L-DOPA preparation. Deuterochloroform as a substitute solvent for Freon 11.